ATE429910T1 - Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen - Google Patents

Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen

Info

Publication number
ATE429910T1
ATE429910T1 AT06291548T AT06291548T ATE429910T1 AT E429910 T1 ATE429910 T1 AT E429910T1 AT 06291548 T AT06291548 T AT 06291548T AT 06291548 T AT06291548 T AT 06291548T AT E429910 T1 ATE429910 T1 AT E429910T1
Authority
AT
Austria
Prior art keywords
treatment
containing chlorine
derivatives containing
prion diseases
guanabenz derivatives
Prior art date
Application number
AT06291548T
Other languages
English (en)
Inventor
Marc Blondel
Stephane Bach
Didier Vilette
Vincent Beringue
Deborah Tribouillard
Original Assignee
Centre Nat Rech Scient
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Agronomique Inst Nat Rech filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE429910T1 publication Critical patent/ATE429910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06291548T 2006-10-04 2006-10-04 Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen ATE429910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291548A EP1908465B1 (de) 2006-10-04 2006-10-04 Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen

Publications (1)

Publication Number Publication Date
ATE429910T1 true ATE429910T1 (de) 2009-05-15

Family

ID=37836911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06291548T ATE429910T1 (de) 2006-10-04 2006-10-04 Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen

Country Status (7)

Country Link
US (1) US20110251428A1 (de)
EP (2) EP1908465B1 (de)
JP (1) JP5186503B2 (de)
AT (1) ATE429910T1 (de)
CA (1) CA2664959A1 (de)
DE (1) DE602006006578D1 (de)
WO (1) WO2008041134A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083397A1 (en) * 2010-12-22 2012-06-28 Silvestre Labs Químia E Farmaceutica Ltda. Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
CN107820518B (zh) 2015-04-08 2023-04-21 英国研究与创新署 用于选择磷酸酶选择性抑制剂和非选择性磷酸酶抑制剂的方法
EP3529237A1 (de) * 2016-10-18 2019-08-28 Institut National de la Sante et de la Recherche Medicale (INSERM) Naturproduktderivate zur hemmung von zellularer nekroptose, ferroptose und oxytose
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
US20210177814A1 (en) 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975533A (en) * 1970-04-29 1976-08-17 Shell Oil Company Therapeutic agents
US3816531A (en) * 1970-07-01 1974-06-11 American Home Prod (2,6-disubstituted benzylidene)amino guanidines and related compounds
US6413962B1 (en) * 1988-05-02 2002-07-02 N. Eric Naftchi Guanidino compounds effective as anesthetics
AU5636300A (en) * 1999-06-25 2001-01-31 Avicena Group, Inc. Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
AU2003282035A1 (en) * 2002-10-18 2004-05-04 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation of s6 kinase activity for the treatment of obestiy
FR2846009B1 (fr) * 2002-10-18 2007-10-12 Centre Nat Rech Scient Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees
FR2893844B1 (fr) * 2005-11-28 2008-02-01 Centre Nat Rech Scient Utilisation du guanabenz et de ses derives pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1908464A1 (de) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Verwendung von Chlorine-Guanabenz-Deriaten zur Behandlung von Polyglutaminexpansionskrankheiten

Also Published As

Publication number Publication date
WO2008041134A3 (en) 2008-06-19
EP1908465B1 (de) 2009-04-29
DE602006006578D1 (de) 2009-06-10
EP2076253A2 (de) 2009-07-08
JP2010505815A (ja) 2010-02-25
WO2008041134A2 (en) 2008-04-10
US20110251428A1 (en) 2011-10-13
EP1908465A1 (de) 2008-04-09
JP5186503B2 (ja) 2013-04-17
CA2664959A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
EA201000050A1 (ru) Замещенные бициклолактамные соединения
ATE548032T1 (de) Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
ATE517882T1 (de) Chinolinderivate
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
ATE547417T1 (de) Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
NO20082096L (no) Azaindol-2-karboksamidderivativer
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
DK2215058T3 (da) Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf
MA32505B1 (fr) 5-alcynyl-pyrimidines
ATE429910T1 (de) Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
EA200700707A1 (ru) Производные 2-ациламинотиазола
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties